SPY331.83+1.77 0.54%
DIA271.60+3.19 1.19%
IXIC10,971.95+30.79 0.28%

Bristol-Myers Squibb's Opdivo Plus Yervoy for Patients with Previously Treated Advanced Hepatocellular Carcinoma Accepted for Priority Review by the FDA

Benzinga · -